RARE 8-K: Ultragenyx Q3 revenue $90.7M, net loss $245.1M ($3.50) on GeneTx charge; reaffirms FY guidance

Ultragenyx Q3 revenue $90.7M, net loss $245.1M ($3.50) on GeneTx charge; reaffirms FY guidance

Ultragenyx Pharmaceutical Inc.

2022-Q3 EPS reported -$7.96 revenue$259,981,000

Total revenue $90.7M (+11% YoY) driven by Crysvita $64.5M (+28% YoY) and Dojolvi $13.3M.

Net loss $245.1M vs $73.0M in Q3 2021; includes $75.2M R&D expense for GeneTx acquisition.

Cash & marketable debt securities $996.2M as of Sep 30, includes $491M from OMERS Crysvita royalty sale.

FY 2022 guidance reaffirmed: Crysvita territories $250-$260M, Dojolvi $55-$65M.

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Ultragenyx Pharmaceutical Inc. reported the quarter ended September 30, 2022 results: revenue $90.7 million, net income $245.1 million, EPS $3.50 per share basic and diluted. Guidance reaffirmed.

Period: the quarter ended September 30, 2022
Revenue: $90.7 million
Net income: $245.1 million
EPS: $3.50 per share basic and diluted
Guidance: reaffirmed
Result: reported results

Exact text from the filing

Third Quarter 2022 Financial Results Net Revenues For the third quarter of 2022, Ultragenyx reported $ 90.7 million in total revenue. Ultragenyx recognized $64.5 million in Crysvita (burosumab) revenue in the Ultragenyx territories, which includes $ 51.3 million in collaboration revenue in the North American profit share territory and net product sales in other regions of $ 13.2 million. Total royalty revenue related to European Crysvita sales was $5.4 million. Dojolvi (triheptanoin) product sales in the third quarter of 2022 were $13.3 million. Mepsevii (vestronidase alfa) product sales for the third quarter of 2022 were $6.0 million. Total revenue for the third quarter of 2022 also includes $1.5 million related to technical assistance following the successful completion of technology transfer activities with Daiichi Sankyo. This compares to total revenue in the third quarter of 2021, which includes $12.1 million related to the technology transfer services which were ongoing at the ti

View on SEC.gov